Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity

Details for Australian Patent Application No. 2010310705 (hide)

Owner Novartis AG

Inventors Szczudlo, Tomasz; Woodman, Richard; Yin, Ophelia

Agent Davies Collison Cave

Pub. Number AU-A-2010310705

PCT Pub. Number WO2011/050120

Priority 61/254,323 23.10.09 US

Filing date 21 October 2010

Wipo publication date 28 April 2011

International Classifications

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

19 April 2012 PCT application entered the National Phase

  PCT publication WO2011/050120 Priority application(s): WO2011/050120

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010310710-System and method for communicating data in a vehicle consist

2010310688-Method of using non-rare cells to detect rare cells